TFC-003

TFC-003 is an ophthalmic fixed-dose combination drug under development for the treatment of primary open-angle glaucoma and ocular hypertension. It is formulated as an eye drop and contains three active pharmaceutical ingredients, though the specific components are not explicitly listed in public sources. The rationale behind this combination is to improve patient compliance by reducing the need to administer multiple separate medications, which is common in glaucoma management. The drug aims to lower intraocular pressure more conveniently for patients who would otherwise require two or three different drugs administered at intervals before sleep[5][1][3]. Developed by Kukje Pharma, TFC-003 has been evaluated in Phase 2 clinical trials comparing its efficacy and safety against established combinations such as dorzolamide/timolol[1][7].

Brand names

TFC-003TFC003TFC 003

Other names

TFC-003TFC003TFC 003